Prostate cancer care is changing fast.<ref>1</ref> Alongside familiar treatments like hormone therapy, surgical gland removal, chemotherapy, and targeted pills, a newer option has entered the conversation for some people. Evolving nuclear medicine treatment, using the theragnostics approach, is offering PSMA-guided therapy with Lutetium-177.<ref>2</ref><ref>3</ref>

This article offers a clear, detailed explanation of the lutetium-177 prostate cancer therapy pathway for patients in plain language. We will present clear definitions, current evidence, results, and risks to help the patient explore the boundaries of lutetium prostate cancer treatment and make an informed decision.

What is Lutetium-177 PSMA Therapy?

Think of lutetium treatment for prostate cancer as a microscopic, guided missile radiopharmaceutical system designed to find and destroy malignant cells throughout the body, even those that have spread.<ref>4</ref><ref>5</ref> In simple terms, this is one of the most exciting advancements in fighting advanced prostate cancer—a highly targeted internal radiation treatment.

In practice, lutetium 177 for prostate cancer is used as Pluvicto treatment (or PSMA-617 / vipivotide tetraxetan).<ref>35</ref> Below, we explain the parts of the drug and their functions.

Structural Components

The medication itself is a radioligand: a two-part drug: one part is a PSMA finder that recognizes prostate cancer cells, and the other part is Lutetium-177, a tiny medical radio source. The two are joined together and given to patients in the form of PSMA lutetium prostate cancer radiopharmaceutical.

Guide PSMA Part

This is the targeting molecule that acts like a GPS. It is specifically designed to bind tightly to the protein Prostate-Specific Membrane Antigen (PSMA).<ref>6</ref><ref>7</ref> The best-known finders are vipivotide tetraxetan (also called PSMA-617) and PSMA-I&T.<ref>6</ref> The component is used solely for transportation and targeting, and it has no therapeutic effect.

Lutetium-177 Particle

Next, there’s the power source, Lutetium-177 (Lu-177)—a beta-emitting radioisotope (radioactive particle) supplied for drug manufacturing in compliance with radiopharmacy standards.<ref>8</ref> It's the part that does the job of killing the cancer cell, but it has a very short reach, like a tiny burst of energy that only damages the immediate surroundings.

General Appearance

177Lu-PSMA Appearance At any hospital, 177Lu-PSMA arrives from the radiopharmacy in a small glass vial (lutetium looks like a clear, colorless solution) inside a lead-shielded container for safety. As a rule, the label displays the drug name, activity (indicated by the “GBq” dose), time, and the small radiation trefoil symbol.<ref>4</ref>

How Lutetium 177 Prostate Cancer Therapy Works

How Lutetium 177 Works for Prostate Cancer After an IV dose of lutetium-177 treatment for prostate cancer, the drug finds PSMA on malignant prostate cells, is taken inside the cell, and the Lu-177 releases short-range radiation (beta particles and gamma photons) that damages the tumor from within.<ref>6</ref> The mechanism of work is clearly determined by its structure: a small PSMA-seeking drug linked to the therapeutic radioisotope Lutetium-177.

Patients should understand that the lutetium treatment for prostate cancer involves internal radiation carried by a medicine (not external-beam radiation), so the internal radiation dose starts where the drug binds.

Targeting Prostate Cancer

PSMA (prostate-specific membrane antigen, also known as GCPII/FOLH1) is a protein located on the surface of prostate cells.<ref>9</ref> Many prostate cancers have a lot more PSMA than normal tissue, so it works like a clear flag that the medicine can aim for.<ref>10</ref>

PSMA Expression

Not every tumor shows PSMA in the same way—some spots are very “hot” for PSMA and others are “cold.”<ref>11</ref><ref>12</ref> Before lutetium 177 prostate cancer treatment, doctors confirm the target using a PSMA PET-CT scan. If the cancer shows a positive signal, the drug should be pursued; if it does not glow, it is not recommended.<ref>13</ref> Lesions with little or no PSMA may not take up the drug well, which is why responses can differ within the same patient.<ref>11</ref><ref>14</ref>

The drug has a PSMA-finder (such as PSMA-617/vipivotide tetraxetan) that binds tightly to PSMA on prostate cancer cells, but not elsewhere. That tight “stick” pulls the Lu 177 PSMA therapy to the prostate cancer tumor rather than to healthy tissue.<ref>4</ref>

Internalized Dose

After the medicine sticks to PSMA on the cell surface, the cancer cell pulls the drug inside (think: a tiny gulp).<ref>15</ref><ref>16</ref> Keeping the drug inside the cell helps the treatment stay where it can do its job. This “stay time” in the tumor, together with the isotope’s decay, is what allows the Lu-177 prostate cancer dose to accumulate to a therapeutic effect.<ref>17</ref>

The process of damaging malignant cells

Lutetium-177 (Lu-177) gives off tiny bursts of energy that travel only a few millimeters.<ref>18</ref> That’s long enough to hit the tumor cell and its close neighbors, but short enough to spare most nearby healthy tissue. Lu-177 naturally loses half of its strength approximately every 6–7 days, so most of the treatment dose is delivered over the first 2–3 weeks following each infusion.<ref>19</ref><ref>20</ref> The duration that the drug remains in each lesion (biologic clearance and biodistribution) plus this physical decay forms the “effective half-life,” which determines how much dose each tumor spot actually receives.<ref>21</ref>

The short distance of work is beneficial because the radiation can still reach nearby cancer cells, even those that have taken up only a small amount of the drug, while primarily not affecting normal tissues that didn’t take up the medicine.<ref>22</ref> This process is often called “cross-fire effect”. This feature is one of the key radiobiological advantages of lutetium 177 prostate cancer treatment.<ref>23</ref>

Stop Cancer Growth

The radiation is harmful to all cells, including the malignant ones. Those tiny energy explosions damage the DNA of prostate cancer cells. With sufficient damage, the cell cannot continue dividing and either shuts down or dies. This DNA-damaging radiation can cause the tumor to shrink or slow its growth.<ref>24</ref><ref>25</ref>

Candidate for Lutetium 177 Prostate Cancer Treatment

The central pillar of prostate cancer patient selection for Lu177 treatment is the theranostics approach: the patient's cancer must demonstrate sufficient expression of PSMA as confirmed by a PSMA PET-CT scan. This confirms that the Lutetium-177 radioligand will target the prostate cancer cells. It’s a strict requirement and lies at the base of its work, as described before. If there’s no PSMA signal in the tumors, the medicine won’t have a target and will not be used.

PSMA-Positive VS PSMA-Negative Cancers Beyond PSMA tumor uptake, a rigorous evaluation is required, focusing on key clinical and laboratory criteria, including adequate organ function (especially bone marrow, kidney, and liver reserves) and overall performance status (as indicated by the ECOG score).

While regional guidelines and drug approvals vary regarding the exact timing and pre-requisite treatments, the general patient characteristics for Lu-177 PSMA candidates worldwide are based on positive clinical trial data, such as the VISION and TheraP trials. We’ll look at general (including cross-border and specific) indications for Lu-177 PSMA prostate cancer treatment below.

Regular: Guideline Approved Indication

The clearest, “standard” use of Lu-177 PSMA comes from the phase 3 VISION study and the first approvals that followed (FDA, EMA).<ref>26</ref> It’s for people with metastatic castration-resistant prostate cancer (mCRPC) with the three main conditions:<ref>27</ref>

They have already been treated with a hormonal therapy, at least one androgen-receptor pathway (ARPI) inhibitor (for example, abiraterone or enzalutamide);<ref>28</ref>
They received at least one taxane chemotherapy (such as Docetaxel);<ref>27</ref>
Their cancer has kept growing.

Prostate cancer cases in these patients must have a clear PSMA uptake (usually higher than in the liver) in all measurable tumor spots and no significant PSMA-negative lesions elsewhere.<ref>29</ref><ref>30</ref>

Physicians also assess overall fitness for lutetium prostate cancer radioligand therapy, including an ECOG performance status of 0–2 (able to be up and about most of the day) and adequate bone marrow, liver, and kidney function to ensure safe administration of the drug.<ref>31</ref>

Expanded Indications

In some places, lutetium prostate cancer solution can be used a bit earlier, thanks to newer studies like PSMAfore. This still applies to people with metastatic castration-resistant prostate cancer (mCRPC) with the following requirements:<ref>31</ref>

Those who have already tried one hormonal pill (an ARPI such as abiraterone or enzalutamide);
Their cancer kept growing;
They haven’t had taxane chemotherapy yet (or aren’t a good fit for it).

The idea is to offer a practical, PSMA-targeted therapy option sooner, thereby delaying the need for chemotherapy and its side effects while still treating the disease.

Off-Label & Lu 177 Prostate Cancer Trials

The following uses are usually not officially approved but may be allowed in some regions through compassionate use programs, clinical trials, or as non-approved treatments. These Lu-177 prostate cancer options are often guided by multidisciplinary tumor boards or experienced nuclear medicine doctors for patients who have exhausted standard therapies.

Advanced Prostate Cancer

In real life, Lu-177 PSMA is sometimes considered when prostate cancer is very advanced and has kept growing despite all standard options.<ref>32</ref> As a rule, patients already had one or more hormonal pills, several rounds of chemotherapy, and even other treatments like Radium-223. In this setting, the primary treatment goal is to alleviate severe symptoms (e.g., bone pain) and, if possible, buy more time when other treatments are ineffective.

Because the body is often worn down at this stage, safety checks matter a lot. Doctors look closely at blood counts, kidney and liver tests, and day-to-day activities. When someone is mostly bedridden (roughly ECOG 3 or higher) or has poor organ function, Lutetium therapy may be too risky; the decision becomes a careful balance of potential relief versus side-effect risk.<ref>27</ref> In brief, it can still help the right person, but the choice is highly individual and guided by what’s safest and most meaningful for the patient.

Metastatic Hormone-Sensitive Prostate Cancer

In some circumstances, physicians are exploring the addition of Lu 177 prostate cancer therapy to the standard treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).<ref>33</ref> For instance, in extra to hormone therapy (ADT), an ARPI or sometimes chemotherapy, Lu177 is used. The idea is to intensify treatment early, especially when the cancer burden is high, to help control the disease longer.<ref>34</ref>

Early results from Lutetium studies, such as PSMAddition, suggest this approach can delay progression when used in carefully selected, PSMA-positive patients alongside usual care<ref>35</ref><ref>36</ref>

Additionally, there is a study, currently in progress, called UpFrontPSMA. Doctors there tested a simple idea: for men with new, PSMA-positive metastatic prostate cancer disease (still hormone-sensitive), give two cycles of Lu-177-PSMA-617 first, then standard chemo, and compare that to chemotherapy alone.<ref>37</ref>

Oligorecurrent Prostate Cancer

In patents, when only a few spots of cancer recur (often one to five lesions), the treatment plan can be more targeted.<ref>38</ref> Oligorecurrent hormone-sensitive prostate cancer (omHSPC) means the cancer had come back in only a few spots and was still sensitive to standard hormone treatment. Doctors may treat those limited areas directly, sometimes in conjunction with Lu-177 PSMA, as explored in the BULLSEYE trial.<ref>39</ref>

The mentioned tactic can help to knock back the visible disease, delay long-term hormone therapy and its side effects, and, in select cases, aim for longer-term control. This approach is often combined with precise local treatments, such as stereotactic body radiotherapy, targeting individual cancer spots.<ref>40</ref>

Localized Prostate Cancer

In some high-volume centers and studies, such as the LUPUS, ROADSTER, and LuTectomy trials, Lu-177 PSMA is being explored for use before surgery or radiation (neoadjuvant lutetium therapy) or after them (adjuvant).<ref>41</ref> The aim is to reach microscopic cancer cells that scans can’t see (micrometastases) and help the main treatment work better over the long term.<ref>22</ref>

For instance, German doctors in the LUPUS study are trying a new delivery method for the 177Lu-PSMA treatment. Instead of giving the radioactive drug through a regular vein, physicians are injecting it directly into the arteries that feed the prostate tumor.<ref>42</ref> This is done before the patient has surgery to remove the prostate.<ref>43</ref>

During the ROADSTER trial, physicians focused on men whose prostate cancer came back only in the prostate area after they had already received radiation treatment.<ref>44</ref> The standard treatment for this recurrence is brachytherapy. This trial is comparing the conventional treatment to a new combination treatment (adding Lu177 to the course). The hope is that the 177Lu-PSMA will help kill any stray cancer cells outside the primary tumor area that the brachytherapy might miss.

Where Doctors May Say “Not Now”

Apart from the obvious situation in which patients don’t fit the therapy, such as insufficient PSMA expression, there are several typical situations patients should be aware of. In the following cases, doctors might refuse to offer Lu177 treatment:

Too frail for safe treatment: People who are mostly bed-bound (ECOG ≥3) or have uncontrolled illness (e.g., severe infection, unstable heart/lung disease) are often not candidates until they’re stabilized.<ref>4</ref>
Very low blood counts: Marked anemia, low white cells/neutrophils, or low platelets—especially after recent chemo/radiation—can make Lu-177 PSMA unsafe until counts recover.<ref>45</ref>
Significant kidney or liver dysfunction: Since the drug is processed and cleared by these organs (so-called biodistribution), poor kidney function or active liver failure may be a contraindication or may require dose adjustments or thorough kidney function monitoring.<ref>6</ref>
Allergy reaction: Known hypersensitivity to the active compound or excipients is a contraindication.<ref>46</ref>
Other red flags: Recent major surgery without recovery, uncontrolled pain requiring urgent different care, or active bleeding can all lead to postponement until safer conditions are met.<ref>4</ref>

Possible Lu177 PSMA Therapy Contrindications

The next best step is to review your case with a urologist, oncologist, or nuclear medicine physician to determine whether you’re a good candidate for Lu-177 PSMA.

Lutetium-177 Success Rate: Studies & Results

To understand the full impact of Lutetium 177 treatment, it is necessary to examine the results from major medical studies, particularly the large Phase 3 trials that led to its global approval.<ref>47</ref> We have organized the information by disease stage and setting because the results differ significantly across scenarios.

How to Read the Results

When reviewing the text, the key success measures are listed below. By breaking down the evidence in this way, you can clearly see how lutetium-177 treatment for prostate cancer has transformed the disease landscape and identify its key benefits.

Life Expectancy: This is the most critical measure. It simply tracks how much longer patients live with the treatment compared to those who didn't receive it.<ref>48</ref> In other words, we can refer to this parameter as the overall survival rate of patients treated with lutetium for prostate cancer.
Progression-Free Survival (PFS): This measures the time before the cancer starts to grow or spread again, as determined by medical scans. A longer PFS indicates that the treatment is controlling the disease more effectively. It also delays cancer growth.<ref>49</ref>
PSA Response: PSA is a common blood marker for prostate cancer. We look for a significant drop (50% or more) in this level, which is a strong indication that the treatment is effectively killing cancer cells. The percentages indicate the number of patients who achieved this significant drop.<ref>50</ref>
Tumor Shrinkage: The objective response rate measures the percentage of patients whose tumors decrease or disappear on medical scans after treatment. A higher rate indicates that more people had a confirmed response to lutetium prostate cancer treatment, suggesting the drug is actively reducing the lesions.<ref>51</ref>

For better understanding, patients should know that improvement is typically measured by comparing patients receiving lutetium for prostate cancer treatment with those on standard care (SoC).

Lu177 Effectiveness Over Prostate Cancer Stages & Settings

For each setting, you’ll see the primary studies, what they compared, and the simple numbers - percentage of lutetium treatment effectiveness. The role of lutetium-177 in prostate cancer treatment and effectiveness is strongest in the most advanced cases and is still being explored in earlier stages.

By examining the provided data, patients can not only explore the results but also understand how lutetium 177 prostate cancer therapy compares to other treatment options. This comparison is fundamental to each study and offers practical value.

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The VISION trial evaluated lutetium 177 prostate cancer treatment in men with very advanced mCRPC who had already been treated with standard hormone pills and one or two types of chemotherapy.<ref>47</ref> The key question was: “Does adding Lutetium-177 improve outcomes over just the best available standard care without it?”.<ref>52</ref>

Measure	Lu-177 + Standard Care	Standard Care Alone	Improvement	Explanation
Tumor shrinkage	29.8%	1.7%	Significantly higher	Tumors visible on scans shrank substantially in nearly 30% of patients.
Delay in cancer growth	8.7 months	3.4 months	5.3 months longer	The time until the cancer grew or spread on scans was more than doubled.
Major PSA drop	46%	9%	5 times higher rate	Nearly half of the patients saw a significant drop in the prostate cancer blood marker.
Life expectancy	15.3 months	11.3 months	4 months longer	Patients lived an average of 4 months longer.

Summary: For men who have exhausted standard treatments, Lu 177 prostate cancer therapy offers a clear, proven benefit in both life expectancy and delaying cancer progression.

In addition, the TheraP trial directly compared lutetium 177 PSMA to the chemotherapy drug cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) who had already received prior chemotherapy (docetaxel).<ref>53</ref>

Measure	Lu-177 Alone	Chemotherapy	Improvement	Explanation
Tumor shrinkage	49%	24%	Significantly higher	Tumors shrank substantially in twice as many patients.
Major PSA drop	66%	37%	Almost two times higher	Effective in achieving PSA response.
Delay in cancer growth	5.9 months	5 months	Almost one month longer	Delaying cancer growth by a small difference.

Summary: Prostate cancer lutetium has a superior alternative to cabazitaxel chemotherapy in this advanced patient setting.

Another lutetium-177 prostate cancer trial was the PSMAfore study, a critical Phase 3 study that focused on men with mCRPC who had not yet received chemotherapy (taxanes).<ref>54</ref> Lutetium 177 treatment for prostate cancer was compared head-to-head with switching to a second, standard hormonal treatment (such as abiraterone or enzalutamide) after the first one failed.

Measure	Lu-177 Alone	Hormone Switch	Improvement	Explanation
Tumor shrinkage	51%	15%	3.4 times higher	Tumors shrank substantially in a far greater number of patients.
Major PSA drop	58%	20%	Significantly higher	Three times more effective in reducing PSA levels.
Delay in cancer growth	11.6 months	5.59 months	6.01 months longer	Doubled the time before the cancer progressed on scans.
Time to symptomatic skeletal event	Longer	Shorter	Significantly prolonged	Delaying painful events related to cancer spreading to the bones.

Summary: The results demonstrated that Lu-177 PSMA is highly effective and better tolerated than standard hormonal therapy in the pre-chemotherapy background. It strongly advocates its use as an earlier line of treatment.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

The PSMAddition trial moves Lu 177 prostate cancer medicine into the earliest metastatic setting. The study focused on men with PSMA-positive metastatic Hormone-Sensitive Prostate Cancer (mHSPC) who were starting first-line systemic treatment. Lutetium for prostate cancer added to the current standard care ( hormone therapy + ARPI) was compared head-to-head against the standard line alone (hormone therapy + ARP).<ref>35</ref><ref>34</ref>

Measure	Lu-177 + Standard Care	Standard Care Alone	Improvement	Explanation
Complete tumor shrinkage	57%	42%	Higher	Achieved a higher rate of complete radiographic response.
Major PSA drop	Higher	Lower	Visible difference	Greater likelihood of extremely low PSA levels.
Time to progression	Significantly delayed	Shorter	Delayed	Slowed the time for the cancer to become resistant.
Life expectancy	Increasing	N/A	Positive trend	The data is still in the early stages, but it is showing promising signs.

Summary: The trial provides compelling evidence that adding Lu-177 PSMA to the standard hormone backbone significantly delays cancer progression in earlier, hormone-sensitive disease and the onset of castration-resistant disease.

Oligometastatic Prostate Cancer Recurrence

The BULLSEYE trial (NCT04443062) tested whether targeting the few recurrent cancer spots with Lu177 PSMA treatment could outperform simply waiting (watchful waiting). It compared PSMA-targeted radiation therapy versus delaying all further treatment to see which approach could postpone the start of long-term hormone therapy the longest.<ref>55</ref>

Measure	Lu-177 + Standard Care	Standard Care Alone	Improvement	Explanation
Time to progression	Not reached (25 months for $50 of patients)	5 months	Significantly delayed	Extended the duration before the disease progressed.
PSA response (≥50% decline)	85-91%	PSA generally increased	Visible difference	Increased likelihood of low PSA.
PSA response (≥90% decline)	>50%	PSA generally increased	Visible difference	Increased likelihood of extremely low PSA.
Complete PSA response (undetectable)	25%	PSA generally increased	Visible difference	Increased likelihood of having a PSA level undetectable.

Summary: Treatment with 177Lu-PSMA-617 significantly prolonged the time to disease progression (defined as the start of ADT therapy) compared with watchful waiting.

Localized Prostate Cancer

LuTectomy/PRELUDE studied men with high-risk localized prostate cancer (cancer that is still only in or near the prostate but is very aggressive). Instead of going straight to surgery, patients in this study received one or two doses of Lu177 PSMA first.<ref>56</ref> This is referred to as lutetium 177 prostate cancer first-line option, so-called neoadjuvant approach. The main goal is to measure how much radiation dose the prostate tumor actually receives, and to see if the drug can shrink or destroy the tumor before surgery, making the operation more successful.<ref>57</ref>

This lutetium-177 prostate cancer study is new and is still in progress; however, preliminary data indicate that PSA levels decreased by 34% after three doses. Some patients had tumor downstaging (cancer reduced to a lower risk group).<ref>58</ref> In addition, it has been reported that lutetium 177 treatment for prostate cancer, followed by surgery, appears to be a surgically safe care with no major anatomical changes or intraoperative complications.<ref>56</ref> For purely localized cancer, Lu-PSMA is promising but experimental. We don’t yet have large, definitive trials showing clear gains in cure rate, so no reliable percentage of “effectiveness” for cure can be quoted yet.

Summary on Lu-177 PSMA Therapy Effectiveness

Overall, Lu-177 PSMA works best in the most advanced prostate cancer. In men with metastatic castration-resistant disease, it shrinks visible tumors in about 30–50% of patients, triggers significant PSA drops in roughly half (often 2–5× more than the other treatments).<ref>59</ref> The therapy likely delays cancer growth, sometimes about twice as long as standard options, while adding a meaningful survival gain in the hardest-to-treat setting.<ref>53</ref>

Used a bit earlier (before chemo), it beats switching to another hormone pill, with far more tumor shrinkage and a much longer time before the cancer grows again.<ref>60</ref> When combined with first-line hormone therapy in newly diagnosed metastatic disease, it further delays progression and pushes more patients toward very low PSA, with survival results still maturing.<ref>61</ref>

In men with just a few recurrent spots, it markedly prolongs the time before new treatment is needed and drives strong PSA responses.<ref>39</ref><ref>62</ref> For cancer still confined to the prostate, early studies show PSA can fall, and surgery remains safe, but it’s experimental, and we don’t yet have proof it improves cure rates.<ref>63</ref>

Lu-177 PSMA Therapy Effectiveness over Prostate Cancer Stages

Essentially, this PSMA-targeted therapy is proving its value across the entire spectrum of prostate cancer, from very advanced cases to those caught at an earlier metastatic stage.<ref>54</ref>

Lutetium 177 Side Effects, Risks & Safety

Lutetium-177 PSMA-based radioligand therapy represents a significant advancement in the management of prostate cancer.<ref>47</ref> Supported by robust data, it is established as a safe and generally well-tolerated treatment.<ref>64</ref> At the same time, patients should be fully informed of the associated side effects, which are detailed in the following comprehensive analysis synthesized from key international clinical Lu 177 therapy guidelines and multi-center trial data.

Complications at a Glance

The information about risks is presented in a table, with the left side showing side effects & reactions grouped by system. On the right side, patients can see the actual percentage (likelihood) of complications. Note that side effect rates (numbers) are often presented as ranges. This is because patient populations and specific trial methods differ across the scientific literature.

Group	Side Effects & Reactions	Likelihood in %
General	Fatigue/Severe fatigue	48–53%/1.3–7%
	Weight loss/Severe weight loss	11%/0.4%
	Edema/Severe edema	10%/0.4%
ENT	Dry mouth/Severe dry mouth	39–66%/0–0.9%
GI	Nausea/Severe nausea	32–36%/0–1.3%
	Constipation/Severe constipation	22%/0.4–1.1%
	Diarrhea/Severe diarrhea	17-19%/0–0.8%
	Vomiting/Severe vomiting	11-19%/0–0.9%
Musculoskeletal	Back pain/Severe back pain	14-24%/1.3–3.6%
	Joint pain/Severe joint pain	20-22%/0–1.1%
	Bone pain/Severe bone pain	11%/2.5%
Nutrition	Loss of appetite/Intense appetite loss	21-22%/0–1.9%
Urinary	Urinary tract infection/Severe UTI	12%/3.8%
Urinary	Acute kidney injury/Severe AKI	3.8-8.5%/1.9–3.2%
Neurological	Dizziness/Severe dizziness	8.3%/0.9%
Neurological	Headache/Severe headache	7%/0.8%
Opthalmological	Dry eye	3%
Laboratory	Anemia/≥G3 anemia	64-67%/7-15%
	Thrombocytopenia/≥G3 thrombocytopenia	30-45%/2.7-9%
	Leukopenia/≥G3 leukopenia	15.7%/4.2%
	Lymphopenia/≥G3 lymphopenia	14.2%/7.8%
	Pancytopenia/≥G3 pancytopenia	1.7%/1.3%
	Neutropenia/≥G3 neutropenia	28-38%/3.5-4.7%
	Decreased eGFR/≥G3 eGFR decrease	43%/3.6%
	Increased eGFR/≥G3 eGFR increase	29%/1.1%
Serious events	Pulmonary embolism	1.1%
	Pneumonia	1.7%
	Second cancers	1.4%
	Therapy-related myeloid neoplasms	1-2%
	Hepatic failure	0,4%
	Stroke	0,2%

The data are gathered and summarized from VISION, TheraP & PSMAfore Trials, EANM/SNMMI Guideline, 12615000912583 Trial, UK eMC EMA Product Details, SWISSMEDIC RMP, HIQA HTA summaries, and REALITY, SWISS registries. For situations where Lu 177 treatment for prostate cancer is used beyond the tested scenarios (off–label), the number may differ.

Practical Risk Controls

Managing the known side effects of Lu-177 therapy is a critical part of the treatment plan. Both the medical team and the patient play a role in monitoring, preventing, and managing potential treatment-related adverse events. Below are the key strategies and routine procedures in place to control risks and maintain your quality of life.

Radiation Exposure Precautions

After treatment, most of the medicine leaves your body in your urine during the first 12 to 48 hours. Drink plenty of water and use the bathroom often to help protect your bladder and kidneys. For a few days, avoid prolonged, close contact with pregnant people and young children.<ref>65</ref>

Fertility Risk

This therapy can temporarily lower sperm production. Use reliable birth control as your doctor recommends. The treatment must not be used during conception, so this matters for partners who could become pregnant.<ref>64</ref>

Higher Risk of Toxicity

Some individuals may require closer monitoring due to possible hematologic toxicity or bone marrow suppression. This includes anyone with low blood counts or cancer spread in the bone marrow, people who have had a lot of chemotherapy or radiation in the past, and those with moderate kidney problems.<ref>66</ref>

References

Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., … Freedman-Cass, D. A. (2024, April). NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024 — Featured Updates to the NCCN Guidelines. JNCCN—Journal of the National Comprehensive Cancer Network, 22(3), 140–150. https://doi.org/10.6004/jnccn.2024.0019. Retrieved November 2025.
Wikipedia. Theranostics. Retrieved November 2025.
University of Iowa Health Care. What is theranostics?. Retrieved November 2025.
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., … Hermann, K. (2023). Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06255-8. Retrieved November 2025.
Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., Wang, M., Chiang, K., Pierce, W. F., Suzman, D. L., Tang, S., Pazdur, R., Amiri-Kordestani, L., Ibrahim, A., & Kluetz, P. G. (2023, May 1). FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 29(9), 1651–1657. https://doi.org/10.1158/1078-0432.CCR-22-2875. Retrieved November 2025.
European Medicines Agency (EMA). PLUVICTO (lutetium (177Lu) vipivotide tetraxetan): EPAR — Product information. Retrieved November 2025.
Kasperzyk, J. L., Finn, S. P., Flavin, R., Fiorentino, M., Lis, R., Hendrickson, W. K., Clinton, S. K., Sesso, H. D., Giovannucci, E. L., Stampfer, M. J., Loda, M., & Mucci, L. A. (2013, December). Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiology, Biomarkers & Prevention, 22(12), 2354–2363. https://doi.org/10.1158/1055-9965.EPI-13-0668. Retrieved November 2025.
Kurth, J., Krause, B. J., Schwarzenböck, S. M., Stegger, L., Schäfers, M., & Rahbar, K. (2018, April 12). External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Research, 8, Article 32. https://doi.org/10.1186/s13550-018-0386-4. Retrieved November 2025.
Bakht, M. K., & Beltran, H. (2025, January). Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nature Reviews Urology, 22(1), 26–45. https://doi.org/10.1038/s41585-024-00900-z. Retrieved November 2025.
Elsässer-Beile, U., Bühler, P., & Wolf, P. (2009, February). Targeted therapies for prostate cancer against the prostate specific membrane antigen. Current Drug Targets, 10(2), 118–125. https://doi.org/10.2174/138945009787354601. Retrieved November 2025.
Gafita, A., Marcus, C., Kostos, L., Schuster, D. M., Calais, J., & Hofman, M. S. (2022, June). Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. American Society of Clinical Oncology Educational Book, 42. https://doi.org/10.1200/EDBK_350946. Retrieved November 2025.
Du, X., Zhang, Y., Jia, Y., & Gao, B. (2025, May). The Development of Al18F-NOTA-FAP-2286 as an FAP-Targeted PET Tracer and the Translational Application in the Diagnosis of Acquired Drug Resistance in Progressive Prostate Cancer. Pharmaceutics, 17(5), 552. https://doi.org/10.3390/pharmaceutics17050552. Retrieved November 2025.
von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., & Schmid, F. A. (2024, December 21). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16(24), 4263. https://doi.org/10.3390/cancers16244263. Retrieved November 2025.
Johns Hopkins Medicine. (2022, November). Finding metastatic prostate cancer that doesn’t make PSMA. Retrieved November 2025.
Maes, J., Gesquière, S., De Spiegeleer, A., Maes, A., & Van de Wiele, C. (2024, September 9). Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy. International Journal of Molecular Sciences, 25(17), 9755. https://doi.org/10.3390/ijms25179755. Retrieved November 2025.
Rajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W. D. W., Bander, N. H., & Rajasekaran, A. K. (2003, December). A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Molecular Biology of the Cell, 14(12), 4835–4845. https://doi.org/10.1091/mbc.e02-11-0731. Retrieved November 2025.
Dadgar, H., Pashazadeh, A., Norouzbeigi, N., Assadi, M., Al-Balooshi, B., Baum, R. P., … Zaidi, H. (2025, March 18). Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer. Theranostics, 15(10), 4368–4397. https://doi.org/10.7150/thno.107963. Retrieved November 2025.
Dash, A., Pillai, M. R. A., & Knapp, F. F., Jr. (2015, February 17). Production of 177Lu for Targeted Radionuclide Therapy: Available Options. Nuclear Medicine and Molecular Imaging, 49, 85–107. https://doi.org/10.1007/s13139-014-0315-z. Retrieved November 2025.
RadiaCode. Lutetium-177 (Lu-177). Retrieved November 2025.
Pillai, M. R. A., Chakraborty, S., Das, T., Venkatesh, M., & Ramamoorthy, N. (2003, August). Production logistics of Lu-177 for radionuclide therapy. Applied Radiation and Isotopes, 59(2–3), 109–118. https://doi.org/10.1016/S0969-8043(03)00158-1. Retrieved November 2025.
Stephen Karesh, PhD. Nuclear Medicine Tutorials. Half-lives of selected radionuclides (PDF). Retrieved November 2025.
Kwon, W.-A., & Joung, J. Y. (2025, October 15). Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions. Cancers, 17(20), 3330. https://doi.org/10.3390/cancers17203330. Retrieved November 2025.
Chi, K. N., Yip, S. M., Bauman, G., Probst, S., Emmenegger, U., Kollmannsberger, C. K., … Saad, F. (2024). 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A review of the evidence and implications for Canadian clinical practice. Current Oncology, 31(3), 1400–1415. https://doi.org/10.3390/curroncol31030106. Retrieved November 2025.
National Cancer Institute. Radiation Therapy to Treat Cancer. Retrieved November 2025.
American Cancer Society. Radiation Therapy to Treat Cancer. Retrieved November 2025.
Konopnicki, A., Zaliznyak, M., Roy, M., … Jana, B. (2024, December 18). The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials. Discover Oncology, 15, Article 791. https://doi.org/10.1007/s12672-024-01680-z. Retrieved November 2025.
Peslier, H., Seegers, V., & Dufour, P.-A. (2025, March 17). Study of predictive factors for response to 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer. Frontiers in Medicine, 12, 1538507. https://doi.org/10.3389/fmed.2025.1538507. Retrieved November 2025.
Feldman, J. (2024, October 14). GU Oncologists Anticipate Earlier Role of Lutetium-177 PSMA-617 in Prostate Cancer. Targeted Oncology, Peers & Perspectives in Oncology. Retrieved November 2025.
Parent, E. E., Savir-Baruch, B., Gayed, I. W., Almaguel, F., Chin, B. B., Pantel, A. R., Armstrong, E., Morley, A., Ippisch, R. C., & Flavell, R. R. (2022, September 1). 177Lu-PSMA Therapy. Journal of Nuclear Medicine Technology, 50(3), 205–212. https://doi.org/10.2967/jnmt.122.263814. Retrieved November 2025.
Seifert, R., Telli, T., Lapa, C., Desaulniers, M., Hekimsoy, T., Weber, W. A., … Fendler, W. P. (2024, June). Safety and efficacy of extended therapy with 177Lu-PSMA: A German multicenter study. Journal of Nuclear Medicine, 65(6), 909–916. https://doi.org/10.2967/jnumed.123.267321. Retrieved November 2025.
Seifert, K. E., Seifert, R., Kessel, K., Roll, W., Schlack, K., Boegemann, M., & Rahbar, K. (2021, July 23). Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. Cancers, 13(15), 3715. https://doi.org/10.3390/cancers13153715. Retrieved November 2025.
UroToday. (2025, February 15). ASCO GU 2025: Survival outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 PSMA-617 (Lu) based on line of therapy. Retrieved November 2025.
Kim, H., Tagawa, S. T., Sartor, O., Saad, F., Reid, A., Sakharova, O., et al. (2024, October 1). PSMAddition: Phase 3 trial of [177Lu]Lu-PSMA-617 plus standard of care (SoC) vs SoC alone in patients with metastatic hormone-sensitive prostate cancer. International Journal of Radiation Oncology • Biology • Physics, 120(2), e546. https://doi.org/10.1016/j.ijrobp.2024.07.1209. Retrieved November 2025.
UroToday. (2025). ESMO 2025: Phase III trial of 177Lu-Lu-PSMA-617 combined with ADT/ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Retrieved November 2025.
Novartis. (2025, June 2). Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. Retrieved November 2025.
ESMO Daily Reporter. (2025, October 19). Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer. Retrieved November 2025.
Azad, A. A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A. J., … UpFrontPSMA Study Team. (2024, October). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25(10), 1267–1276. https://doi.org/10.1016/S1470-2045(24)00440-6. Retrieved November 2025.
Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., … ESTRO–ASTRO Consensus Panel. (2020, July). Defining oligometastatic disease from a radiation oncology perspective: an ESTRO–ASTRO consensus document. Radiotherapy and Oncology, 148, 157–166. https://doi.org/10.1016/j.radonc.2020.04.042. Retrieved November 2025.
Privé, B. M., Janssen, M. J. R., van Oort, I. M., Muselaers, C. H. J., Jonker, M. A., de Groot, M., Zamecnik, P., Letteboer, T., van Kalmthout, L. W. M., Verzijlbergen, F. J., Boerman, O. C., Oprea-Lager, D. E., Hendrikse, N. H., Schalken, J. A., Witjes, J. A., Nagarajah, J., & Adema, G. J. (2021, November 4). Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials, 22, 768. https://doi.org/10.1186/s13063-021-05733-4. Retrieved November 2025.
Ma, T. M., Czernin, J., Felix, C., Alano, R., Wilhalme, H., Valle, L., … Kishan, A. U. (2023, July). LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol). BJU International, 132(1), 65–74. https://doi.org/10.1111/bju.15988. Retrieved November 2025.
UroToday. (2024). AUA 2024: Phase II Study of Neoadjuvant Lu-177 PSMA-617 in Patients with High-Risk Localized Prostate Cancer Undergoing Radical Prostatectomy (PRELUDE Trial). Retrieved November 2025.
UroToday. (2025). ASCO GU 2025: A Phase I/II Study of Neoadjuvant Intra-Arterial Administration of 177Lu-lutetium vipivotide tetraxetan in subjects with high-risk localized or locally advanced prostate cancer (LUPUS). Retrieved November 2025.
MedPath. A Phase I/II Study of Neoadjuvant, Intra-arterial Administration of [177Lu]Lu-PSMA-617 in Subjects with High-risk, Localised or Locally Advanced Prostate Cancer who are Candidates for Radical Prostatectomy (LUPUS). Registration: CTIS2022-500838-28-00. Retrieved November 2025.
Mendez, L. C., Dhar, A., Laidley, D., Liu, S. K., Morton, G. C., Loblaw, A., Chung, H. T., Chung, P. W., McIntosh, L. C., & Quon, H. (2023, April 20). The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER). BMC Cancer, 23, 362. https://doi.org/10.1186/s12885-023-10851-0. Retrieved November 2025.
Medicines and Healthcare products Regulatory Agency (MHRA). (2022, April 5). Lutetium (177Lu) vipivotide tetraxetan: Treatment protocol — Information for patients. Retrieved November 2025.
U.S. Food and Drug Administration. (2022, March). PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use — Highlights of Prescribing Information. Retrieved November 2025.
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., et al. (2021, June 23). Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 385(12), 1091–1103. https://doi.org/10.1056/NEJMoa2107322. Retrieved October 2025.
Delgado, A., & Guddati, A. K. (2021, April 15). Clinical endpoints in oncology – a primer. American Journal of Cancer Research, 11(4), 1121–1131. Retrieved November 2025.
NCBI Bookshelf. Background — Progression-Free Survival. Retrieved November 2025.
Grayling, M. J., McMenamin, M., Chandler, R., Heer, R., & Wason, J. M. S. (2022, January 26). Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials. BMC Cancer, 22, 111. https://doi.org/10.1186/s12885-022-09227-7. Retrieved November 2025.
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009, January). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228–247. https://doi.org/10.1016/j.ejca.2008.10.026. Retrieved November 2025.
Endocyte, Inc., a Novartis Company. (2022, September 14). VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (Clinical Protocol No. PSMA-617-01, Version 7.0). Retrieved November 2025.
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., … TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. (2021, February 27). 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. The Lancet, 397(10276), 797–804. https://doi.org/10.1016/S0140-6736(21)00237-3. Retrieved November 2025.
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., Roubaud, G., Študentová, H., Nagarajah, J., Mellado, B., Montesa-Pino, Á., Kpamegan, E., Ghebremariam, S., Kreisl, T. N., Wilke, C., Lehnhoff, K., Sartor, O., & Fizazi, K.; PSMAfore Investigators. (2024, September 28). ^177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. The Lancet, 404(10459), 1227–1239. https://doi.org/10.1016/S0140-6736(24)01653-2. Retrieved November 2025.
Privé, B. M., Janssen, M. J. R., van Oort, I. M., Muselaers, C. H. J., Jonker, M. A., de Groot, M., … Nagarajah, J. (2020, September 14). Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 20, 884. https://doi.org/10.1186/s12885-020-07386-z. Retrieved November 2025.
Eapen, R. S., Buteau, J. P., Jackson, P., Mitchell, C., Oon, S. F., Alghazo, O., … Hofman, M. S. (2024, March). Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): A single-centre, single-arm, phase 1/2 study. European Urology, 85(3), 217–226. https://doi.org/10.1016/j.eururo.2023.08.026. Retrieved November 2025.
UroToday. (2023). EAU 2023: LuTectomy — A Prospective Study of Dosimetry, Safety, and Potential Benefit of Upfront 177Lu-PSMA-617 Radioligand Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. Retrieved November 2025.
Golan, S., Frumer, M., Zohar, Y., Rosenbaum, E., Yakimov, M., Kedar, D., … Bernstine, H. (2023, April). Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial. European Urology Oncology, 6(2), 151–159. https://doi.org/10.1016/j.euo.2022.09.002. Retrieved November 2025.
Rohith, G. (2021, October 1). VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. Indian Journal of Urology, 37(4), 372–373. https://doi.org/10.4103/iju.iju_292_21. Retrieved November 2025.
Sayyid, R., & Klaassen, Z. (2025, August 18). Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club. UroToday. Retrieved November 2025.
Tagawa, S. T., Sartor, O., Piulats, J. M., Saad, F., Fizazi, K., Reid, A., … on behalf of the PSMAddition investigators. (2025, October 19). Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). ESMO 2025 presentation. Retrieved November 2025.
UroToday. (2025). ASCO 2025: Lutetium-177 PSMA-617 in oligo-metastatic hormone-sensitive prostate cancer (BULLSEYE trial). Retrieved November 2025.
Bolek, H., Coskun Yazgan, S., Ceylan, F., Esteban-Villarrubia, J., Arslan, C., Kuş, T., … Ürün, Y. (2025, February 25). Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS). European Journal of Cancer, 217, 115226. https://doi.org/10.1016/j.ejca.2025.115226. Retrieved November 2025.
U.S. Food and Drug Administration. (2025, March). PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use — Highlights of Prescribing Information. Retrieved November 2025.
Ladrière, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., & Vigne, J. (2023, April 13). Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals. Pharmaceutics, 15, 1240. https://doi.org/10.3390/pharmaceutics15041240. Retrieved November 2025.
European Commission. (2022, December 9). Pluvicto: Annexes to the Commission Implementing Decision — Community Register of Medicinal Products. Retrieved November 2025.

</reflinks>

Lutetium-177 PSMA Treatment for Prostate Cancer